WE NEED YOUR HELP!

Please send your reports for these potential safety issues* listed in the table below.

Medicine	Potential safety issue	Active monitoring period ends*
Rivaroxaban	Atrial fibrillation	1 September 2011
Simvastatin	Joint pain and swelling	1 September 2011
Quetiapine	cardiomyopathy	1 September 2011

 

• The scheme does not replace routine adverse reaction reporting.  Find out how to report at:  http://www.otago.ac.nz/carm or http://www.medsafe.govt.nz

newzealand.govt.nz